Single pembrolizumab treatment causing profound durable response in a patient with pulmonary pleomorphic carcinoma
Hirokazu Tokuyasu, Soichiro Ishikawa, Hiromitsu Sakai and 2 more
Respiratory Medicine Case Reports · 2019
doi:10.1016/j.rmcr.2019.100879 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
We report a case of a 73-year-old man diagnosed with pulmonary pleomorphic carcinoma who showed profound durable response after a single treatment with pembrolizumab. The patient underwent a diagnostic workup in our hospital due to a hoarseness of voice. Chest computed tomography revealed a massive pulmonary tumor in the left upper lobe and multiple nodules in the both lung fields. Histological examination of a transbronchial lung biopsy specimen revealed pulmonary pleomorphic carcinoma. First-line treatment with pembrolizumab was discontinued after a single administration due to treatment-related pneumonitis. However, durable response has been observed over 17 months to date. Keywords: Durable response, Non-small cell lung cancers, Pembrolizumab, Pulmonary pleomorphic carcinoma, Single administration, Treatment-related pneumonitis
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.